CN Mobile Logo

Search form


Multiple Myeloma

Multiple Myeloma

In this interview we discuss the standard of care and current treatment options for patients with multiple myeloma.

The stem cell transplantation utilization rate in the United States increased from 2008 to 2014, but was lower among Hispanics and non-Hispanic blacks compared with non-Hispanics whites.

Combination treatment with pembrolizumab, pomalidomide, and low-dose dexamethasone resulted in durable responses in patients with relapsed or refractory multiple myeloma.

Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma.

Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.

Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.

In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.


Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.